Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Compugen Ltd. stock logo
CGEN
Compugen
$1.43
-1.4%
$1.40
$1.13
$2.66
$127.61M2.61369,766 shs160,154 shs
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
$1.65
+6.5%
$1.37
$0.91
$6.22
$138.13M2.152.57 million shs2.52 million shs
Exozymes Inc. stock logo
EXOZ
Exozymes
$13.99
-6.1%
$12.09
$8.50
$23.99
$117.07MN/A18,810 shs10,893 shs
HEXO Corp. stock logo
HEXO
HEXO
$0.71
+2.5%
$0.87
$0.66
$3.84
$31.24M1.35880,508 shs305,500 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Compugen Ltd. stock logo
CGEN
Compugen
0.00%+4.32%-2.03%-25.26%-40.57%
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
0.00%+4.03%+0.65%-16.67%-72.47%
Exozymes Inc. stock logo
EXOZ
Exozymes
0.00%0.00%+38.86%-15.00%+1,489,999,900.00%
HEXO Corp. stock logo
HEXO
HEXO
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Compugen Ltd. stock logo
CGEN
Compugen
1.9114 of 5 stars
3.54.00.00.02.50.00.0
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
4.2742 of 5 stars
3.14.00.04.22.61.71.3
Exozymes Inc. stock logo
EXOZ
Exozymes
N/AN/AN/AN/AN/AN/AN/AN/A
HEXO Corp. stock logo
HEXO
HEXO
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Compugen Ltd. stock logo
CGEN
Compugen
3.00
Buy$4.00179.72% Upside
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
2.29
Hold$5.36225.07% Upside
Exozymes Inc. stock logo
EXOZ
Exozymes
0.00
N/AN/AN/A
HEXO Corp. stock logo
HEXO
HEXO
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest HEXO, EDIT, EXOZ, and CGEN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2025
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$8.00 ➝ $4.00
4/29/2025
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
4/28/2025
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$3.00
4/28/2025
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$3.00
(Data available from 5/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Compugen Ltd. stock logo
CGEN
Compugen
$27.59M4.63N/AN/A$0.73 per share1.96
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
$35.84M3.85N/AN/A$4.27 per share0.39
Exozymes Inc. stock logo
EXOZ
Exozymes
N/AN/AN/AN/AN/AN/A
HEXO Corp. stock logo
HEXO
HEXO
$146.20M0.21N/AN/A$2.44 per share0.29
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Compugen Ltd. stock logo
CGEN
Compugen
-$18.75M-$0.1671.50N/AN/A2.67%2.62%1.36%8/5/2025 (Estimated)
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
-$153.22M-$3.04N/AN/AN/A-340.96%-80.13%-50.99%8/6/2025 (Estimated)
Exozymes Inc. stock logo
EXOZ
Exozymes
N/AN/A0.00N/AN/AN/AN/AN/A
HEXO Corp. stock logo
HEXO
HEXO
-$845.90M-$5.21N/AN/AN/A-235.33%-74.04%-32.51%N/A

Latest HEXO, EDIT, EXOZ, and CGEN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/19/2025Q1 2025
Compugen Ltd. stock logo
CGEN
Compugen
-$0.06-$0.08-$0.02-$0.08$3.70 million$2.28 million
5/12/2025Q1 2025
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
-$0.51-$0.43+$0.08-$0.92$0.79 million$4.66 million
5/12/2025Q1 2025
Exozymes Inc. stock logo
EXOZ
Exozymes
N/A-$0.22N/A-$0.22N/AN/A
3/5/2025Q4 2024
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
-$0.39-$0.55-$0.16-$0.55$37.17 million$30.60 million
3/4/2025Q4 2024
Compugen Ltd. stock logo
CGEN
Compugen
$0.07-$0.07-$0.14-$0.07$17.47 million$1.47 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Compugen Ltd. stock logo
CGEN
Compugen
N/AN/AN/AN/AN/A
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
N/AN/AN/AN/AN/A
Exozymes Inc. stock logo
EXOZ
Exozymes
N/AN/AN/AN/AN/A
HEXO Corp. stock logo
HEXO
HEXO
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Compugen Ltd. stock logo
CGEN
Compugen
N/A
4.14
4.14
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
N/A
3.75
3.75
Exozymes Inc. stock logo
EXOZ
Exozymes
N/AN/AN/A
HEXO Corp. stock logo
HEXO
HEXO
0.01
0.41
0.24

Institutional Ownership

CompanyInstitutional Ownership
Compugen Ltd. stock logo
CGEN
Compugen
12.22%
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
71.90%
Exozymes Inc. stock logo
EXOZ
Exozymes
N/A
HEXO Corp. stock logo
HEXO
HEXO
7.78%

Insider Ownership

CompanyInsider Ownership
Compugen Ltd. stock logo
CGEN
Compugen
9.50%
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
2.10%
Exozymes Inc. stock logo
EXOZ
Exozymes
N/A
HEXO Corp. stock logo
HEXO
HEXO
4.69%
CompanyEmployeesShares OutstandingFree FloatOptionable
Compugen Ltd. stock logo
CGEN
Compugen
7089.24 million80.76 millionOptionable
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
23083.71 million80.98 millionOptionable
Exozymes Inc. stock logo
EXOZ
Exozymes
298.37 millionN/AN/A
HEXO Corp. stock logo
HEXO
HEXO
1,27744.00 million41.93 millionOptionable

Recent News About These Companies

Tilray wins dismissal of $8M shareholder lawsuit
A 614-Square-Foot Art Nouveau Apartment in France Gets a Bold Update
Tech30: most promising Indian startups of 2024
Is Hexo Corp (HEXO) Stock a Good Investment?
Two cannabis stocks analysts love right now

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Compugen stock logo

Compugen NASDAQ:CGEN

$1.43 -0.02 (-1.38%)
Closing price 04:00 PM Eastern
Extended Trading
$1.44 +0.02 (+1.05%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Editas Medicine stock logo

Editas Medicine NASDAQ:EDIT

$1.65 +0.10 (+6.45%)
Closing price 04:00 PM Eastern
Extended Trading
$1.66 +0.02 (+0.91%)
As of 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Exozymes stock logo

Exozymes NASDAQ:EXOZ

$13.99 -0.91 (-6.11%)
As of 04:00 PM Eastern

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.

HEXO stock logo

HEXO NYSE:HEXO

HEXO Corp., together with its subsidiaries, produces, markets, and sells cannabis in Canada. The company offers its adult-use and medical products under the HEXO brand name. It also provides cannabis beverages under the Little Victory, House of Terpenes, Mollo, Veryvell, and XMG brands; and cannabis products under UP Cannabis, Original Stash, and Up brand names. It has a strategic alliance with Tilray Brands, Inc. The company was formerly known as The Hydropothecary Corporation and changed its name to HEXO Corp. in August 2018. HEXO Corp. was founded in 2013 and is headquartered in Gatineau, Canada. As of June 22, 2023, HEXO Corp. operates as a subsidiary of Tilray Brands, Inc.